Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Localization, distribution, and connectivity of neuropeptide Y in the human and porcine retinas - a comparative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Melanopsin expressing human retinal ganglion cells: Subtypes, distribution and intraretinal connectivity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sex differences in the photoperiodic regulation of RF-Amide related peptide (RFRP) and its receptor GPR147 in the syrian hamster

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jens Olsen
  • Kenneth Forsstrøm Jensen
  • Daniel Sloth Olesen
  • Ann Knoop
Vis graf over relationer

AIM: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment.

MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages.

RESULTS: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887).

CONCLUSION: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.

OriginalsprogEngelsk
TidsskriftJournal of Comparative Neurology
Vol/bind7
Udgave nummer5
Sider (fra-til)411-419
ISSN0021-9967
DOI
StatusUdgivet - 2018

ID: 52174644